Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.

Saved in:
Bibliographic Details
Title: Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.
Authors: Ebrahimi H; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Dizman N; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.; MD Anderson Cancer Center, Houston, TX, USA., Meza L; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.; Yale University School of Medicine, New Haven, CT, USA., Malhotra J; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Li X; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Dorff T; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Frankel P; Department of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Llamas-Quitiquit M; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Hsu J; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Zengin ZB; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.; Yale University School of Medicine, New Haven, CT, USA., Alcantara M; Department of Immuno-Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Castro D; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Mercier B; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Chawla N; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Chehrazi-Raffle A; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Barragan-Carrillo R; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Jaime-Casas S; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Govindarajan A; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Gillece J; Translational Genomics Research Institute (TGen), Phoenix, AZ, USA., Trent J; Translational Genomics Research Institute (TGen), Phoenix, AZ, USA., Lee PP; Department of Immuno-Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Parks TP; Osel, Inc., Mountain View, CA, USA., Takahashi M; Miyarisan Pharmaceutical Co., Ltd, Tokyo, Japan., Hayashi A; Miyarisan Pharmaceutical Co., Ltd, Tokyo, Japan., Kortylewski M; Department of Immuno-Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA, USA., Caporaso JG; Translational Genomics Research Institute (TGen), Flagstaff, AZ, USA., Lee K; Translational Genomics Research Institute (TGen), Flagstaff, AZ, USA., Tripathi A; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. atripathi@coh.org., Pal SK; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. spal@coh.org.
Source: Nature medicine [Nat Med] 2024 Sep; Vol. 30 (9), pp. 2576-2585. Date of Electronic Publication: 2024 Jun 28.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1546-170X
DOI:10.1038/s41591-024-03086-4